Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06677892 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT06677892 · ClinicalTrials.gov record · last posted 2026-08-13

A Study of Maribavir in Adults With Post-transplant Cytomegalovirus (CMV) Infection in Belgium

Study acronym: MARIBEL
StatusActive, Not Recruiting
PhaseNot specified
SponsorTakeda
Started2025-02-24
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
Cytomegalovirus (CMV) is a common virus that infects many people. It can cause serious illness in people with weak immune systems especially in those undergoing transplants. Maribavir is a medicine approved for treating CMV infection in adults after transplant. The main aim of this study is to check the use of maribavir and learn how safe and effective in treating adults with CMV infection after transplant in Belgium in line with the Belgian reimbursement criteria. During the study, a participant's data will be collected for 2 years. The study does not have fixed visits to the hospital, but it is recommended collect data from routine visits and contacts.

Protocol amendment history 2 changes detected by DataLookout

2026-08-14
Enrollment closed, study ongoing
2026-08-14
Enrollment reduced: 75 → 66 participants
Trial Details
NCT Number NCT06677892
Lead Sponsor Takeda
Conditions Cytomegalovirus (CMV)
Enrollment 66 participants
Start Date 2025-02-24
Primary Completion 2026-08-01 (estimated)
Study Completion 2026-09-01 (estimated)
Updated on ClinicalTrials.gov 2026-08-13